ClinicalTrials.gg
CompletedNCT00473655Updated Dec 16, 2010Results posted

Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients

A Phase 4 interventional study of rosuvastatin in Hypertriglyceridemia, Hyperlipoproteinemia Type IV and Hyperlipoproteinemia Type V, sponsored by AstraZeneca. Completed at 3 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies in Hypertriglyceridemia by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hypertriglyceridemia · AstraZeneca.

Enrollment
6th of 12
334 · median 224
Started
2007
the only one that year
Phase 4
Only one
of the 12
Registered
1st of 12
by date

Among the 12 studies in Hypertriglyceridemia by AstraZeneca, this one is the 6th largest by enrollment, is the only one that started in 2007, is the only one in phase 4, and was the 1st registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

None of the 12 studies in Hypertriglyceridemia by AstraZeneca is open now. The open studies under Hypertriglyceridemia, anywhere →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Hypertriglyceridemia by AstraZeneca as a file.
02

Study summary

The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.

03

Conditions studied

  • Hypertriglyceridemia
  • Hyperlipoproteinemia Type IV
  • Hyperlipoproteinemia Type V
  • Hyperlipoproteinemia Type IIb
  • Hyperlipidemia

Keywords

  • Triglycerides
  • hypertriglyceridemia
  • statins
  • rosuvastatin
  • hyperlipoproteinemia
  • Fredrickson Type IIb or IV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years, both genders, without any previous treatment with statins or other lipid lowering drugs for at least 6 months
  • With elevated triglycerides above 200 and below 800mg/dl and willing to follow all study procedures including assisting to clinics, fasting before blood samples and signing a written consent

Exclusion criteria

Exclusion Criteria:

  • High levels of low-density lipoprotein cholesterol (LDL-C)
  • Unstable cardiovascular condition or awaiting a myocardial revascularization
  • Congestive cardiac failure
  • Uncontrolled diabetes
  • Cancer
  • Uncontrolled hypothyroidism
  • Familial hypercholesterolemia
  • Liver/muscle disease
  • Pregnancy
  • Other
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
334 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)

    Reduction from baseline to end of study

    Time frame: 8 weeks

Secondary outcomes

  1. Non-HDL-C Reduction

    Reduction from baseline to end of study

    Time frame: 8 weeks

  2. LDL-C Reduction

    Reduction from baseline to end of study

    Time frame: 8 weeks

  3. Total Cholesterol Reduction

    Reduction from baseline to end of study

    Time frame: 8 weeks

  4. HDL-C Increase

    Increase from baseline to end of study

    Time frame: 8 weeks

  5. ApoA1 Levels

    Change in the levels from baseline to end of study

    Time frame: 8 weeks

  6. hsCRP Reduction

    Reduction from baseline to end of study

    Time frame: 8 weeks

  7. Adverse Events Reported

    Number of participants with AEs and SAEs reported

    Time frame: 8 weeks

  8. ApoB Levels

    Change in the levels from baseline to end of study

    Time frame: 8 weeks

07

Results

Posted Jun 8, 2010

Participant flow

All participants where outpatients recruited from clinical centers. Recruitment began on August 2007 and ends on October 2008

Participant flow — Overall Study
MilestoneRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Started111112111
Completed102107103
Not completed958
Withdrew: Lost to follow-up958

Outcome measures

PrimaryChange (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)

Reduction from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dL
Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)
mg/dLRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Change (Reduction) in Triglycerides Levels From Baseline to End of Treatment (Week 8)67.95 ± 128.4678.61 ± 121.5122.31 ± 120.54
SecondaryNon-HDL-C Reduction

Reduction from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dL
Non-HDL-C Reduction
mg/dLRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Non-HDL-C Reduction52.76 ± 48.0861.31 ± 46.631.06 ± 37.41
SecondaryLDL-C Reduction

Reduction from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dL
LDL-C Reduction
mg/dLRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
LDL-C Reduction42.23 ± 28.5853.22 ± 32.80-2.66 ± 28.78
SecondaryTotal Cholesterol Reduction

Reduction from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dL
Total Cholesterol Reduction
mg/dLRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Total Cholesterol Reduction49.73 ± 41.1363.32 ± 42.97-1.44 ± 34.98
SecondaryHDL-C Increase

Increase from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dL
HDL-C Increase
mg/dLRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
HDL-C Increase3.49 ± 7.162.49 ± 5.781.95 ± 7.42
SecondaryApoA1 Levels

Change in the levels from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dl
ApoA1 Levels
mg/dlRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
ApoA1 Levels4.66 ± 23.386.79 ± 18.602.65 ± 19.40
SecondaryhsCRP Reduction

Reduction from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/L
hsCRP Reduction
mg/LRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
hsCRP Reduction0.19 ± 1.160.11 ± 0.35-0.01 ± 1.00
SecondaryAdverse Events Reported

Number of participants with AEs and SAEs reported

Time frame:
8 weeks
Reported as:
Number · Participants
Adverse Events Reported
ParticipantsRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Adverse Events Reported272920
SecondaryApoB Levels

Change in the levels from baseline to end of study

Time frame:
8 weeks
Reported as:
Mean · mg/dl
ApoB Levels
mg/dlRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
ApoB Levels-27.05 ± 26.92-36.81 ± 23.511.43 ± 26.03

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 10 mg—1/111 (0.9%)9/111 (8.1%)
Rosuvastatin 20 mg—0/112 (0%)12/112 (10.7%)
Placebo—0/111 (0%)12/111 (10.8%)
Most frequent serious events
Most frequent serious events
EventRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Femur And Rotula Right Fracture That Required HospitalizationMusculoskeletal and connective tissue disorders1/1110/1120/111
Most frequent other events
Most frequent other events
EventRosuvastatin 10 mgRosuvastatin 20 mgPlacebo
Upper respiratory infectionRespiratory, thoracic and mediastinal disorders3/1115/1125/111
Urinary tract infectionRenal and urinary disorders1/1111/1123/111
CephaleaNervous system disorders1/1113/1121/111
PharyngotonsillitisRespiratory, thoracic and mediastinal disorders2/1111/1120/111
Leg EdemaRenal and urinary disorders0/1110/1122/111
DizzinessNervous system disorders1/1112/1121/111
Back painMusculoskeletal and connective tissue disorders1/1112/1120/111

Baseline characteristics

Age Continuous
Age Continuous(Years)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
Age52.57 ± 12.7753.14 ± 1251.48 ± 13.4752.4 ± 12.74
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
Female526754173
Male594557161
Arterial Hypertension
Arterial Hypertension(Participants)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
Arterial Hypertension363534105
Diabetes mellitus
Diabetes mellitus(Participants)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
Diabetes mellitus12161341
Body mass index continuous
Body mass index continuous(Kg/m2)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
Body mass index30.72 ± 5.1129.77 ± 4.0430.36 ± 4.9030.28 ± 4.71
HDL-C levels, continuous
HDL-C levels, continuous(mg/dL)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
HDL-C33.50 ± 7.5234.05 ± 6.8832.30 ± 6.4933.28 ± 6.99
LDL-C, continuous
LDL-C, continuous(mg/dL)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
LDL-C129.24 ± 28.23130.51 ± 29.19129.77 ± 31.10129.84 ± 29.45
TG levels, continuous
TG levels, continuous(mg/dL)Rosuvastatin 10 mgRosuvastatin 20 mgPlaceboTotal
Tg levels319.51 ± 131.95296.78 ± 95.19309.46 ± 99.55308.25 ± 110.22
08

Study locations

3 sites
  • Research Site
    Mexico City, DF, Mexico
  • Research Site
    Guadalajara, Jalisco, Mexico
  • Research Site
    Monterrey, Nuevo Leon, Mexico
09

References and documents

Publications

  • Talavera JO, Martinez G, Cervantes JL, Marin JA, Rodriguez-Briones I, Gonzalez JG, Ocampo R, Sanchez-Mijangos H, Bernal-Rosales LP, Polanco A. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients. Curr Med Res Opin. 2013 Apr;29(4):379-86. doi: 10.1185/03007995.2013.766590. Epub 2013 Feb 21. PubMed 23323877 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2007
First posted
May 15, 2007
Start
Jan 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Jun 8, 2010
Last update
Dec 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00473655
Lead sponsor
AstraZeneca
First posted
May 15, 2007
Start date
Jan 2007
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Jun 8, 2010
Last update
Dec 16, 2010

Study contacts

Ana Polanco, MD
study director · AstraZeneca Mexico
Ana Polanco, MD
study chair · AstraZeneca Mexico
Juan Talavera, MD
principal investigator · IMSS
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion